Substrate Utilization and Hemodynamics During Control and Dobutamine Canine Studies
| Parameter | 1-11C-PA scan | 17-11C-HDA scan | ||||
|---|---|---|---|---|---|---|
| Normal | Dobutamine | Normal | Dobutamine | |||
| Fatty acid utilization (nmol/g · min) | 72 ± 1 | 202 ± 181 | 89 ± 9 | 135 ± 51 | ||
| Palmitate utilization (nmol/g · min) | 25 ± 2 | 50 ± 9 | 33 ± 5 | 39 ± 11 | ||
| Glucose utilization (nmol/g · min) | 214 ± 11 | 305 ± 24 | 213 ± 86 | 0 ± 514 | ||
| Lactate utilization (nmol/g · min) | 179 ± 33 | 28 ± 19 | 161 ± 52 | 131 ± 42 | ||
| Double product (mm Hg · beats per min) | 2,403 ± 83 | 8,393 ± 346 | 3,283 ± 445 | 12,076 ± 68 | ||
1-11C-PA = 1-11C-palmitate.
Comparison of substrate utilization in canine studies obtained by direct arterial and coronary sinus samples. As expected, dobutamine increases cardiac work and metabolism.